Franklin Genomic Advancements ETF
HELX
8 hedge funds and large institutions have $2.97M invested in Franklin Genomic Advancements ETF in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
92% more capital invested
Capital invested by funds: $1.55M → $2.97M (+$1.43M)
60% more funds holding
Funds holding: 5 → 8 (+3)
7.01% more ownership
Funds ownership: 15.89% → 22.9% (+7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.26M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$244K |
| 3 |
LPL Financial
San Diego,
California
|
+$84.9K |
| 4 |
HHGA
Halbert Hargrove Global Advisors
Long Beach,
California
|
+$55.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$51.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$66 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $1.18M | +$1.26M | +41,030 | New |
|
|
GT
2
Glenview Trust
Louisville,
Kentucky
| $941K | – | – | – |
|
|
3
LPL Financial
San Diego,
California
| $489K | +$84.9K | +2,768 | +19% |
|
|
4
Citadel Advisors
Miami,
Florida
| $230K | +$244K | +7,966 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $61.1K | +$51.2K | +1,668 | +371% |
|
|
HHGA
6
Halbert Hargrove Global Advisors
Long Beach,
California
| $52K | +$55.3K | +1,801 | New |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $12K | – | – | – |
|
|
HI
8
Harbour Investments
Madison,
Wisconsin
| $3.92K | +$4.17K | +136 | New |
|
9
JP Morgan Chase
New York
| $1 | – | – | – |
|
|
10
Osaic Holdings
Scottsdale,
Arizona
| – | -$66 | -2 | Closed |
|
HELX Hedge Fund Activity: Q4 2024 in Review
8 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q4 2024, worth a combined $2.97M — up 92% from $1.55M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new HELX positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $1.26M. The largest seller was Osaic Holdings, exiting entirely with an estimated $66 sold.
- 8 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q4 2024, up from 5 in Q3 2024.
- Funds reported $2.97M of Franklin Genomic Advancements ETF stock for Q4 2024, up 92% quarter-over-quarter.
- 4 funds opened new Franklin Genomic Advancements ETF positions in Q4 2024 and 1 closed out, a net change of +3 holders.
- The largest Franklin Genomic Advancements ETF buyer in Q4 2024 was Jane Street, an estimated $1.26M added.
- The largest Franklin Genomic Advancements ETF seller in Q4 2024 was Osaic Holdings, an estimated $66 sold.
Based on aggregated 13F filings for Q4 2024.